|
|
|
|
| 2003 Grants |
| Investigator |
Institution |
Project Title |
Grant Duration |
Amt Granted |
| Laura D. Carbone,
M.D. * |
University of
Tennessee
Memphis, Tenn. |
Pamidronate Inhibition
of SSc Fibroblast Precursors |
Two Years |
$150,000 |
| Keith B. Elkon, M.D. * |
University of Washington
Seattle, Wash. |
The Role of Akt and the Regulation
of Apoptosis in Scleroderma Fibroblasts |
Two Years |
$150,000 |
| Barry L. Gruber, M.D. * |
SUNY at Stony Brook
Stony Brook, N.Y. |
Mast cells activate fibroblasts
in scleroderma via protease activated receptors (PAR's) |
Two Years |
$150,000 |
| Dinesh Khanna, M.D. ** |
University of California
- Los Angeles
Los Angeles, Calif. |
Quality of life in scleroderma
lung disease |
Two Years |
$50,000 |
| Lauren H. Kim, M.D. ** |
Boston Medical Center
Boston, Mass. |
Abnormalities of gene expression
in scleroderma fibroblasts |
Two Years |
$50,000 |
| Anna Ludwicka-Bradley, PhD
* |
Medical University of South
Carolina
Charleston, S.C. |
The role of thrombin and
its receptor on myofibroblast differentiation in scleroderma
lung fibrosis |
Two Years |
$150,000 |
| Virginia Steen, M.D. * |
Georgetown University
Washington, D.C. |
Outcome Studies in Systemic
Sclerosis using the Pittsburgh Scleroderma Databank |
Two Years |
$150,000 |
| Maria Suarez-Almazor, M.D.,
Ph.D. * |
Baylor College of Medicine
Houston, Texas |
Outcome Assessment in Scleroderma |
Two Years |
$149,719 |
| Kenneth J. Warrington, M.D.
* |
University of Tennessee
Memphis, Tenn. |
Anti-fibrogenic Type I Collagen-specific
Th1 Lymphocytes in Scleroderma |
Two Years |
$150,000 |
| Vladimir Yurovsky, Ph.D.
* |
University of Maryland at
Baltimore
Baltimore, M.D. |
Role of TRAIL in Pulmonary
Fibrosis in Scleroderma |
Two Years |
$150,000 |
| |
|
Total Granted 2003: |
|
$1,299,719 |
|
| * Grants
funded by the Scleroderma Foundation.
** Physician Scientist Development Awards collaboratively
funded by the Scleroderma Foundation and the Arthritis Foundation. |
Back
to Our Researchers |
|
|
|
|
